Personalized structural biology reveals the molecular mechanisms underlying heterogeneous epileptic phenotypes caused by de novo KCNC2 variants

Souhrid Mukherjee,1,6 Thomas A. Cassini,11,17 Ningning Hu,8,9,17 Tao Yang,5,17 Bian Li,1,5,6,17 Wangzhen Shen,8 Christopher W. Moth,6 David C. Rinker,4,6 Jonathan H. Sheehan,6,10 Joy D. Cogan,2 Undiagnosed Diseases Network, John H. Newman,3 Rizwan Hamid,2 Robert L. Macdonald,5,8 Dan M. Roden,5,7,18 Jens Meiler,4,5,6,7,12,13,14 Georg Kuenze,4,6,12,* John A. Phillips,2,* and John A. Capra1,6,7,15,16,*

Summary

Whole-exome sequencing (WES) in the clinic has identified several rare monogenic developmental and epileptic encephalopathies (DEE) caused by ion channel variants. However, WES often fails to provide actionable insight for rare diseases, such as DEEs, due to the challenges of interpreting variants of unknown significance (VUS). Here, we describe a “personalized structural biology” (PSB) approach that leverages recent innovations in the analysis of protein 3D structures to address this challenge. We illustrate this approach in an Undiagnosed Diseases Network (UDN) individual with DEE symptoms and a de novo VUS in KCNC2 (p.V469L), the Kv3.2 voltage-gated potassium channel. A nearby KCNC2 variant (p.V471L) was recently suggested to cause DEE-like phenotypes. Computational structural modeling suggests that both affect protein function. However, despite their proximity, the p.V469L variant is likely to sterically block the channel pore, while the p.V471L variant is likely to stabilize the open state. Biochemical and electrophysiological analyses demonstrate heterogeneous loss-of-function and gain-of-function effects, as well as differential response to 4-aminopyridine treatment. Molecular dynamics simulations illustrate that the pore of the p.V469L variant is more constricted, increasing the energetic barrier for K⁺ permeation, whereas the p.V471L variant stabilizes the open conformation. Our results implicate variants in KCNC2 as causative for DEE and guide the interpretation of a UDN individual. They further delineate the molecular basis for the heterogeneous clinical phenotypes resulting from two proximal pathogenic variants. This demonstrates how the PSB approach can provide an analytical framework for individualized hypothesis-driven interpretation of protein-coding VUS.

Introduction

The advent of cheaper and more accurate DNA-sequencing technologies has enabled the integration of genetic information into diverse areas of medicine. For example, more than 70% of rare diseases are thought to have a genetic cause, and recent efforts have identified the causal variants for thousands of Mendelian diseases.1–3 However, causal variants have not been identified for approximately half (~3,000) of known rare genetic diseases,1,4 and sequencing often fails to lead to actionable insights, even after expert clinical evaluation through programs such as the NIH's Undiagnosed Diseases Network (UDN).2–9

Many computational methods have been developed for interpreting variants observed in clinical sequencing.10–13 However, they have substantial weaknesses and often disagree.14–18 Commonly used tools provide only ill-defined, categorical variant classifications, such as “pathogenic” and “benign” and fail to propose specific hypotheses about the underlying molecular effects of variants. A prediction that a variant is pathogenic is not of much clinical use without a testable prediction of the mechanisms of its pathogenicity, pleiotropic effects, and possible insights to treatment.

Motivated by the challenges of variant interpretation, recent advances in experimental approaches for protein structure determination19–24 and recent improvements to
the accuracy of prediction, modeling, and analysis of native 3D protein structural models, we propose a variant interpretation paradigm. Our “personalized structural biology” approach focuses on making mechanistic predictions about the effects of the variant(s) observed in individuals in the context of their genetic background via computational and experimental evaluation of protein structure and function. We demonstrate the power of this approach on two candidate variants of unknown significance (VUS) in KCNC2, the gene encoding the homo-tetrameric voltage-gated potassium channel Kv3.2, one variant from an individual with an unsolved epilepsy-like disease enrolled in the UDN and another variant from a recent case report with epilepsy-like phenotypes; however, no functional validation was done for the variant.

Developmental epileptic encephalopathies (DEE) are a group of devastating disorders in which epileptic activity contributes to cognitive and behavior impairment in addition to underlying developmental pathologies. Genetic etiologies are thought to be the cause of a substantial proportion of individuals with DEE, and with recent advances in genetic testing technology, many DEE variants have been discovered. The underlying genetic mechanisms are diverse, but defects in neuronal ion channels are thought to be a common cause of DEE. For example, the initial discovery that Dravet syndrome is caused by variants in SCN1A has been followed by the demonstration that variants in many voltage-gated potassium (Kv) channels can cause DEE. The largest family of these channels is the Kv family, with 12 subfamilies whose alpha subunits are encoded by approximately 40 genes. The Kv3 subfamily influences rapid firing of inhibitory interneurons in the central nervous system. The general mechanism of Kv3.2 channel gating is thought to be similar to other closely related voltage-gated potassium ion channels. Kv channels consist of four homologous subunits, with each monomer having six transmembrane helical domains (S1-S6). S1-S4 form the voltage-sensing domain (VSD) and S5-S6 from all four subunits form the membrane pore. A linker domain between S4 and S5 connects the VSD to the pore-forming units. The VSD undergoes conformational changes between the open and closed state of the channel, and the coupling between the S4-S5 linker and the S6 pore-forming unit is responsible for the voltage-dependent gating of the channel. With a pronounced inward movement of the positively charged S4 voltage sensor, the S4-S5 linker is pushed downward, which causes the S6 helix to constrict the pore, thus closing the channel. This gating mechanism is made possible by the presence of a proline-valine-proline (PVP) motif, which acts as a hinge domain in the S6 helix. The hinge domain allows the S6 pore-forming helix to kink at the flexible PVP motif to open and close the channel pore. Other members of this subfamily have been implicated as a potential causes of DEE and other epilepsy-like symptoms with discoveries of variants in genes encoding Kv3.1 and Kv3.3. More recently variants in KCNC2, which is highly expressed in GABAergic interneurons, have been suggested to be linked to DEE-like phenotypes, with possibly dominant negative effects. However, the links and their mechanisms are yet to be established.

Our work makes four main contributions. First, we demonstrate via expression and electrophysiology analyses that the two candidate KCNC2 variants (p.V469L, p.V471L) have heterogeneous loss-of-function and gain-of-function effects, despite both affecting the essential hinge region of Kv3.2 responsible for channel gating. Second, our protein structural modeling and molecular dynamics (MD) simulations rationalize the mechanistic basis for the phenotypic heterogeneity of these variants. Third, our results combine to validate links between KCNC2 variants and heterogeneous DEE phenotypes. Finally, our analyses provide a blueprint for integrating genetics, expression analysis, electrophysiology, and protein structural modeling to develop mechanistic understanding of the molecular effects of de novo variants in rare disease.

Methods

Structural modeling of Kv3.2

The tetrameric structural model of human Kv3.2 (UniProtKB accession number: Q96PR1-1; modeled residues: 1-484) was generated by homology modeling using the molecular modeling software suite Rosetta (version 3.10). The shaker family voltage-dependent potassium channel (Kv1.2-Kv2.1 paddle chimera channel) resolved to 2.4 Å (PDB: 2R9R) was used as a template. The percent identity between the aligned positions of the sequences of Kv3.2 and the template structure was 42.8%, sufficiently high for the chimera channel structure to serve as a reliable template. A starting partial tetrameric model of Kv3.2, which only covered aligned residues, was generated by threading the sequence of Kv3.2 onto the template structure using the corresponding sequence alignment as a guide. Full models were created using the Rosetta comparative modeling (RosettaCM) protocol guided by the RosettaMembrane energy function in a C4 symmetry mode. The boundaries of membrane-spanning segments were calculated using the PPM server based on the starting model. The boundaries were used to impose membrane-specific Rosetta energy terms on residues within the theoretical membrane bilayer. A total of 1,000 full tetrameric models were generated using RosettaCM. The lowest-energy model was selected as the final model for structure-based analysis in this work.

MD system setup

The Kv3.2 channel domain (residues L211-M484) was embedded in a POPC (palmitoyloleoyl-phosphatidylcholine) bilayer (~240 lipid molecules per leaflet) using the membrane builder tool of CHARMM-GUI. The system was solvated in TIP3P water containing 0.15 M of neutralizing KCl. Three K⁺ ions were placed in the channel selectivity filter at coordination sites S0, S2, and S4 by inferring their positions from the crystal structure of the Kv1.2-Kv2.1 chimeric channel (PDB: 2R9R). Another K⁺ ion was placed below the selectivity filter in the aqueous channel cavity (termed Scav site) and used for running umbrella simulations.
During conventional MD simulations, the position of the cavity K⁺ ion was constrained by imposing distance restraints to the selectivity filter residue T437.

Conventional MD simulations

MD simulations of the Kv3.2 channel in POPC membranes were performed with AMBER16 using the ff14SB force field for proteins and the Lipid17 force field. The system was simulated in four replicas with a total simulation time of ~1 μs. Bonds involving hydrogen atoms were constrained with SHAKE. Non-bonded interactions were evaluated with a 10 Å cutoff, and long-range electrostatic interactions were evaluated by the particle-mesh Ewald method. Each MD system was first minimized using a four-step energy minimization procedure: Minimization of only lipids was followed by minimization of only water + ions, and minimization of protein before the whole system was minimized. With protein and ions restrained to their initial coordinates, the lipid and water were heated to 50 K over 1,000 steps with a step size of 1 fs in the NVT ensemble using Langevin dynamics with a rapid collision frequency of 10,000 ps⁻¹. The system was then heated to 100 K over 50,000 steps with a collision frequency of 1,000 ps⁻¹ and finally to 310 K over 200,000 steps and a collision frequency of 100 ps⁻¹. After changing to the NPT ensemble, restraints on protein and ions were gradually removed over 500 ps. The system was equilibrated for another 10 ns at 310 K with weak positional restraints (with a force constant of 5 kcal mol⁻¹ Å⁻²) applied to protein Cz atoms. The protein restraints were then gradually removed over 20 ns, and production MD was conducted for 260 ns using a step size of 2 fs, constant pressure periodic boundary conditions, anisotropic pressure scaling, and Langevin dynamics.

Subsequent to running production MD, molecules were reimagined back into the simulation box using CPPTRAJ and the final 200 ns of each MD replica were analyzed. The Kv3.2 channel was aligned to the first MD frame and the channel pore radius was measured with HOLE by taking conformations of Kv3.2 at every 1 ns.

Umbrella MD simulations

To estimate the free energy of K⁺ ion permeation through the cytosolic gate of Kv3.2 wild-type (WT), p.V469L, and p.V471L channels, we calculated the potential of mean force (PMF) of moving a K⁺ ion up the pore axis past the cytosolic constriction site and into the cavity below the selectivity filter. The center of mass of the backbone atoms of the selectivity filter residues (T437-V440 of all four subunits) was defined as the origin of the pore axis. Umbrella potentials (with a spring constant of 10 kcal mol⁻¹ Å⁻²) were placed at 0.5 Å intervals in the range from Z = −11 Å (below selectivity filter) to Z = −44 Å (in cytosol), making a total of 67 umbrella simulations for each 1D PMF. In addition, to ensure that the K⁺ ion remained in the vicinity of the pore axis when it was no longer constrained by the S6 helices (i.e., was in bulk solvent), we used a method described in Fowler and Sansom and applied a flat-bottomed cylindrical constraint with a radius of 8 Å and a spring constant of 10 kcal mol⁻¹ Å⁻². Starting configurations for each umbrella window were prepared by taking the last frame from the conventional MD simulation and gradually pulling the cavity K⁺ ion from Scav into cytosolic solvent over 10 ns using a spring constant of 10 kcal mol⁻¹ Å⁻². To ensure that the direction of the pore axis was well defined and did not change during the simulation, the positions of the backbone atoms of the first two helix turns of S6 (W448-G454) were constrained by a harmonic potential with a force constant of 5 kcal mol⁻¹ Å⁻² during the pulling and umbrella simulations. Each umbrella simulation was run for 10 ns and repeated twice for each of the original four MD replicas. The WHAM method as implemented in the program by Grossfield was used to remove the umbrella biases and calculate 1D PMFs. A final 1D PMF was calculated for Kv3.2 WT, p.V469L, and p.V471L, respectively, by averaging the individual PMFs for each variant, and the height of the free energy barrier relative to the bulk solvent was measured.

Heterologous expression of Kv3.2 ion channel and whole-cell voltage clamp electrophysiology

WT Kv3.2, p.V469L, and p.V471L channel plasmids (1 ng/μL for each plasmid) were separately transfected with green fluorescent protein (GFP as marker to identify successful ion channel expression) into Chinese hamster ovary (CHO) cells using 10 μL Eugen6e 6 (Promega), following the manufacturer’s cell transfection instructions. Two days post transfection, cells with green color were selected for patch clamp experiments.

Whole-cell voltage clamp experiments were performed at room temperature (22°C–23°C) with 3–5 mΩ patch microelectrodes, by using a MultiClamp 700B amplifier and DigiData 1550B low-noise data acquisition system (Molecular Devices, Sunnyvale, CA). The extracellular solution contained (in mmol/L) NaCl 145, KCl 1.0, MgCl₂ 1.0, CaCl₂ 1.8, glucose 10, and HEPES 10; pH 7.4, adjusted with NaOH. The pipette (intracellular) solution contained (in mmol/L) KCl 110, MgCl₂ 1.0, ATP-K₂ 5.0, BAPTA-K₄ 5.0, and HEPES 10; pH 7.2, adjusted with KOH. Data acquisition was performed using pClamp 10.7 software (Molecular Devices), sampling at 1 kHz and low-pass-filtered at 5 kHz. Activating current was elicited with 1-s depolarizing pulses from a holding potential of −80 mV at 10-mV increments, and tail current was recorded on return to −40 mV. Pulses were delivered every 15 s. The current-voltage relationships were analyzed by fitting the Boltzmann equation to the data: \( I = I_{max}/[1 + exp [(V_t - V_{o.5})/k] ] \), where \( I_{max} \) is the maximal current, \( V_t \) is the test potential, \( V_{o.5} \) is the membrane potential at which 50% of the channels are activated, and \( k \) is the slope factor. Current densities (pA/pF) were obtained after normalization to cell surface area calculated by the Membrane Test in pClamp 10.7. A potassium channel blocker 4-aminopyridine (4-AP) at 200 μM (Sigma-Aldrich, St. Louis, MO, USA) was used to test the sensitivity of WT Kv3.2 and two variant (p.V469L and p.V471L) channels to drug block using a 1-s repetitive pulsing protocol from a holding potential of −80 mV to a testing potential of +60 mV.

DNA constructs for WT and variants of KCNC2

The coding sequences DNA of human Homo sapiens potassium voltage-gated channel subfamily C member 2 (KCNC2) (NM_139137.4) was subcloned into pcDNA3.1(+)/C-(-)DYK expression vector with an equipped FLAG tag (DYKDDDDK) in C-terminal (GenScript, NJ, USA). The mutant KCNC2 variants Kv3.2-p.V469L and Kv3.2-p.V471L cDNA constructs were generated by using a pair of designed overlapping primers for the PCR in the QuickChange Site-Directed Mutagenesis Kit (Agilent, USA, cat. no. 200523) and by using the PCR Overlap Extension method to introduce the mutation site. Both variants were confirmed by DNA sequencing.

Western blot

To detect the Kv3.2 protein expression and to perform protein functional analysis, the WT and two mutated cDNA plasmids
were transfected to CHO stable cells (ATCC, USA) by X-tremeGENE 9 DNA Transfection Reagent (Roche). The transfected cells were collected and lysed in modified radio-immuno-precipitation assay lysis buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 1% NP-40, 0.2% sodium deoxycholate, 1 mM EDTA), and 1% protease inhibitor cocktail (Sigma-Aldrich, USA). Collected protein samples were subjected to gel electrophoresis using 4%–12% BisTris NuPAGE precast gels (Invitrogen Life Technologies, USA) and transferred to PVDF-FL membranes (MilliporeSigma, USA). Primary antibody against FLAG epitope tag located on FLAG fusion proteins (Sigma-Aldrich, polyclonal ANTI-FLAG, rabbit host. F7425) was used to detect the Kv3.2 protein by indirect immunofluorescent staining at a 1:500 dilution. Anti-Na+/K+ ATPase antibody (Developmental Studies Hybridoma Bank, anti-bodies at the University of Iowa for use in research, USA) at a 1:1,000 dilution was used as an internal quality control. IRDye conjugated secondary anti-rabbit antibody (LI-COR Biosciences, USA) was used at a 1:10,000 dilution. The membranes were scanned using the Odyssey Infrared Imaging System, and the integrated density value of bands was determined using the Odyssey Image Studio software (LI-COR Biosciences, USA).

Clinical report
The UDN subject described here is a male who was born at 39 weeks gestation to a then 26-year-old G1P1 mother via C section due to transverse positioning. His maternal grandfather had a single seizure, but there was no other family history of seizures. At 4 months of age he was diagnosed with infantile spasms, which persisted despite treatment with zonisamide, pyridoxine, ACTH, and ketogenic diet. Around 18 months of age he developed generalized tonic clonic seizures and was diagnosed with Lennox-Gastaut syndrome. He continued to have frequent myoclonic absence seizures and occasional generalized tonic clonic seizures that were refractory to valproic acid, clobazam, lamotrigine, rufinamide, and cannabidiol. Phenobarbital was trialed but not tolerated due to mood changes.

He also has global developmental delay that was noted by 10 months of age in the gross and fine motor domain. He sat at 24 months and walked at 3.5 years. Central hypotonia with extremiti hypertonia was noted, but he did not have any hypertonia posturing or dystonia. His reflexes were normal. He was able to walk, but with a wide-based and ataxic gait.

On physical examination at 5.5 years his height and weight were both 5%–10%. He was microcephalic with a head circumference of <3%. He had no dysmorphic features. He was alert and interactive, but he did not speak with any clear words. Central hypotonia with extreme extremiti hypertonia was noted, but he did not have any hypertonia posturing or dystonia. His reflexes were normal. He was able to walk, but with a wide-based and ataxic gait. Neuroimaging studies included two MRIs and one CT of the brain, performed when he was less than 1 year old, which were normal. His most recent EEGs, performed around age 4 years, showed generalized seizures and multifocal epileptogenicity. The first captured three typical spells of staring with rhythmic head and extremiti movements. These corresponded to poorly formed generalized spike and wave discharges most prominent in the bilateral posterior regions that were thought to likely be generalized seizures. Soon after that an EEG captured occasional medium to high-voltage sharp waves most prominent in the bilateral mesial frontal regions, but he did not show any seizures. Both were on a background of generalized, non-specific, cerebral dysfunction.

Basic laboratory evaluation including complete blood counts and a comprehensive metabolic panel have been normal. A screen for metabolic disease including ammonia, lactate, pyruvate, plasma amino acids, urine organic acids, and a plasma acylcarnitine profile revealed only minor non-specific abnormalities as well. Additional tests of pipercolic acid, alpha aminoadipic semialdehyde, creatine metabolites, and CDG testing were reported as WNL. At age 4 years, a lumbar puncture was performed with normal cell counts, protein, and glucose. CSF amino acids and neurotransmitter studies including 5-methyltetrahydofolate, neopterin, tetrahdrobioteparin, 5-hydroxyindoleacetic acid, homovanillic acid, 3-O-methyldopa, and pyridoxal 5-phosphate were normal as well.

Our UDN subject with the de novo p.V469L. KCNC2 variant shared several DEE-like symptom phenotypes that overlapped those of the previously characterized individual10 with the de novo p.V471L variant. These included DEE with seizures refractory to medications, developmental delay, microcephaly, and identical missense de novo KCNC2 variants separated by two codons (p.V469L and p.V471L). However, they differ in that the reported individual had also had complete absence of speech, dystonia, decreased myelination around frontal and occipital horns of the lateral ventricles and later widespread hypomyelination, spastic tetraplegia, myoclonic jerks, and opisthotonos attacks. Work in the Vanderbilt UDN is carried out under the oversight of the Vanderbilt institutional review board.

Results
UDN individual with DEE-like symptoms
A 4-year-old boy at the Vanderbilt University UDN site presented with DEE-like phenotypes, including multiple types of refractory seizure and global developmental delay. Around 18 months of age, he developed generalized tonic clonic seizures, and was diagnosed with Lennox-Gastaut syndrome, a severe form of DEE. However, he continued to have frequent myoclonic absence seizures and oc- cisional generalized tonic clonic seizure. A full clinical report is available in the supplemental text.

Initial sequencing of the individual on an epilepsy gene panel through Athena that covered ARHGEF9, ARX, CBL5L, CNTPAP1, FOXG1, GABRG2, GRIN2A, KCN2, MECP2, NRXN1, PCDH19, PNKP, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, SCN1A, SCN1B, SCN2A, SCN8A, SCN9A, SLC25A22, SLC2A1, SLC9A3, SPTAN1, STXBP1, SYNAP1, TCF4, TREX1, UBE3A, and ZEB2 was negative. Deletion analysis of SCN1A was negative as well. Secondary findings, metabolic screens, and mitochondrial DNA sequencing were also negative.

Following the negative epilepsy panel result, whole-exome sequencing revealed a candidate variant in a voltage-gated potassium channel Kv3.2, KCNC2 c.1405G>T (p.V469L). Sanger sequencing confirmed this variant. This variant was not seen in either of his parents, and therefore it was presumed to be de novo. This variant is in the conserved hinge motif of the channel which is critical for channel gating (Figure 1). The potential relevance of this variant is supported by another recently reported discovered
candidate heterozygous variant also located in the hinge domain of KCNC2 (c.1411G>C, p.V471L), only two amino acids away from p.V469L, which has been observed in two European individuals. The UDN subject and the previously reported individual shared the phenotypes of DEE, seizures refractory to medications, developmental delay, and other neurological features.

Figure 1. Candidate pathogenic variants in KCNC2 are nearby, but have different structural contexts in Kv3.2
(A) Homo-tetrameric structure of Kv3.2. The complete structural model of Kv3.2 (KCNC2) was generated using RosettaCM from Kv1.2-Kv2.1 paddle chimera channel (PDB: 2R9R, 42.8% sequence identity). Four homologous subunits form the tetrameric channel pore structure; chain A is shown in color. Each monomeric subunit has intracellular N terminal domain (black) and six transmembrane helical domains. S1-S4 form the voltage sensing domain (VSD) (beige). The S4-S5 linker (magenta) is the force transducer between the VSD and the channel pore, formed by the S5 (yellow) and the S6 (red) helices. The S5-S6 linker (orange) acts as the selectivity filter, allowing only potassium ions through the channel. The candidate variant (p.V469L) is located in the PVP motif (purple; residues 468–470) which acts a hinge domain facilitating channel gating. The previously discovered variant (p.V471L) suspected to also cause DEE-like symptoms is located adjacent to the PVP motif.
(B) A view of the carbon backbone of the S6 helix, showing the PVP hinge region. The valines at positions 469 (blue) and 471 (green) are shown.
(C) A view of the channel pore formed by the tetrameric structure of Kv3.2, showing the selectivity filter (orange) and the hinge domain (purple).
(D) A closer view of the channel pore with reference amino acids valine at positions 469 (deep blue) and 471 (teal) shown, alongside variant leucine residues (light blue and cyan). Residue 469 extends into the pore, while residue 471 faces away from the pore.
(E) A view of the carbon backbone of the native (valine) and substituted (leucine) amino acids at positions 469 and 471.
and microcephaly. However, their phenotypes differed in that the previously reported individual also had complete absence of speech, dystonia, decreased myelination around frontal and occipital horns of the lateral ventricles, spastic tetraplegia, myoclonic jerks, and opisthotonos attacks.

To evaluate the evidence for these VUS and propose specific functional hypotheses, we assessed the effects of these variants on protein expression, structure, and function with experimental and computational methods.

**Structural modeling suggests distinct functional effects for candidate KCNC2 variants**

To evaluate the potential effects of the KCNC2 variants at the molecular level, we constructed a homology model of its tetrameric structure based on a high-resolution (2.4 Å) structure of the Kv1.2-Kv2.1 paddle chimera channel (PDB: 2R9R) using the Rosetta molecular modeling suite. The homo-tetrameric Kv3.2 model, with six transmembrane helical domains (S1-S6) is shown in Figure 1A. The PVP motif ranges between residues 468 and 470 on the S6 helix and facilitates channel gating. The variants of interest p.V469L and p.V471L are adjacent to the PVP motif (Figure 1B). The channel pore is formed by the S5 and S6 helices of all four chains together (Figure 1C), and the PVP motifs on all four helices act together for channel gating. This region is almost entirely conserved among vertebrates (Figure S1A). Furthermore, previous studies have shown that altering the central hydrophobic residues in Kv1.1 channels from valine to isoleucine affects channel kinetics, stability, and conformational dynamics. The sequence similarity between the template and Kv3.2 was 42.8%, and the sequence similarity over the force-transducing and pore-forming domains (S4-S6), was even higher (>55%).

The UDN subject’s variant (p.V469L) results in a conservative substitution, which changes the hydrophobic valine at the core of the PVP motif to leucine, another hydrophobic amino acid. However, the p.V469L variant is predicted to have a deleterious effect on the protein by commonly used variant effect prediction tools such as CADD and GERP (Figure S1B). The residue at position 469 faces into the channel pore (Figure 1D), and while conservative amino acid substitutions do not usually have severe effects, in this case, the bulkier leucine amino acid (Figure 1E) is less likely to lead to a decrease in the pore radius as the residue faces outward. In this case, we hypothesize that the molecular effect of the p.V471L variant would widen the pore and increase its tendency to remain open, leading to more ions passing through than normal and thus a gain-of-function phenotype. We also predict that the channel gating will be affected by the bulkier leucine residue; however, not to the extent of the p.V469L variant since p.V471L faces away from the channel pore.

p.V469L causes mixed gain and loss of channel function, while p.V471L causes gain of function

To quantify the effects of the candidate variants we quantified the electrophysiological function of Kv3.2, potassium channel currents for WT Kv3.2 and the two disease-causing variants (p.V469L and p.V471L) in CHO cells. The proteins were expressed in a homo-tetrameric model, with all four chains carrying the variant, in each case. The WT form of Kv3.2 showed a very fast deactivation, in accordance with previously characterized behavior of the Kv3.2 channel (Figures 2A and S2). KCNC2 is primarily expressed in the brain, where its product Kv3.2 contributes to the fast repolarization of action potentials in neurons of the central nervous system. Therefore, short spike duration and rapid deactivation of Kv3.2 channels are important for normal physiology.

The electrophysiological profiles for the p.V469L variant (Figures 2B and S2) compared with the WT Kv3.2 had a lower peak current and much longer deactivation tails. The peak current for the p.V469L mutant was less than half that of WT (Figure 2D), with a much slower deactivation and a slight negative shift of ~10 mV (Figure 2E). In contrast, the electrophysiological profile for p.V471L (Figures 2C and S2) showed a much higher peak current than WT, with a longer deactivation tail. The p.V471L peak current was 1.5 times that of the WT channel (Figure 2D), with a moderately slower deactivation, but a drastic negative shift of ~28 mV (Figure 2E). The very slow deactivation and slightly negative voltage shift observed for p.V469L and moderately slow deactivation and dramatically negative voltage shift for p.V471L align with the structural hypothesis of loss-of-function and gain-of-function phenotypes, respectively. However, p.V469L also exhibits some potential gain-of-function effects with lower current and very slow deactivation, but a mild hyperpolarizing shift in steady-state activation, ameliorating the loss-of-function phenotype. For each variant, the same amount of plasmid was injected, and the behavior of the proteins at their native levels of expression was analyzed.

We further characterized the effect of the variants on channel function by administration of the voltage-gated potassium channel blocker 4-AP. Kv3.2 is very sensitive to 4-AP. 4-AP is known to approach the channel lumen from the cytoplasmic side, and bind the open channel weakly. Once bound, the channel becomes...
biased toward the closed state, and 4-AP binds strongly to the closed conformation, blocking the channel. Interestingly, 4-AP blocked the channel activity similarly for the WT and p.V469L Kv3.2 (Figures 2F and S3). Both experienced >70% decreases in activity (p > 0.05, n = 6). In contrast, the gain-of-function p.V471L variant was resistant to 4-AP compared with WT and p.V469L (p < 0.0001 for both, n = 6), showing a less than 30% reduction in activity (Figures 2F and S3). This could be due to the p.V471L variant stabilizing the channel in the open conformation, thereby making 4-AP less effective in closing the channel and less likely to bind. These results further support the contrasting functional mechanisms we propose for p.V469L and p.V471L.

p.V469L expression is lower while p.V471L expression is higher than WT
Rare pathogenic protein-coding variants, in addition to causing changes to protein structure and molecular function, can also lead to altered protein expression in cells. We compared the levels of protein present in cells for the WT and two Kv3.2 variants with an immunoblot analysis (western blot).

The homomeric p.V469L Kv3.2 was present at less than half the amount for homomeric WT, while the levels for homomeric p.V471L Kv3.2 were greater than 1.5 times that of WT (Figure 3). Thus, expression differences likely contribute to the loss- and gain-of-function effects for the two variants, respectively. However, while the expression levels could cause the observed differences in the peak currents for the two variants (Figure 2), differences in protein levels alone cannot explain the slowed deactivation dynamics of the p.V469L channel. Thus, both differences in the molecular function and expression levels of these KCNC2 variants contribute to their phenotypic effects.

p.V469L constricts the channel pore in MD simulations increasing the energetic barrier for K⁺ ion permeation
To explore the molecular basis for the functional changes caused by p.V469L and p.V471L, we performed MD simulations of these ion channel variants and of WT Kv3.2 in

Figure 2. Candidate Kv3.2 variants cause loss and gain of channel function
(A) Representative potassium current traces for wild-type (WT) Kv3.2 in CHO cells recorded by voltage clamp. WT shows the characteristic current amplitude and fast deactivation (short deactivating tail currents).

(B) Current traces for the p.V469L variant show lower peak current and very slow deactivation.

(C) Current traces for the p.V471L variant demonstrate much higher current and moderately slowed deactivation compared with WT. Each voltage clamp used the protocol shown in the insert of (A). The deactivation tails are compared in greater detail in Figures S2A–S2C.

(D) Current versus steady-state voltage (I-V) curves for WT Kv3.2, p.V469L, and p.V471L. The p.V469L variant showed a much lower current at steady state, while the p.V471L variant showed increased current at steady state.

(E) Current versus voltage plots for the tails for each variant p.V469L has a slight negative shift (~10 mV), while p.V471L has a large negative voltage shift (~28 mV). Each group considered 6 to 10 cells.

(F) Percentage of channel activity (steady-state current) blocked by 200 μM 4-aminopyridine (4-AP), a known voltage-gated potassium channel blocker, for WT, p.V469L, and p.V471L. The WT and p.V469L Kv3.2 were similarly blocked (p > 0.05, n = 6 for each), but p.V471L was resistant to 4-AP blockage (p < 0.0001, n = 6). Error bars represent standard deviations. Figures S3A–S3C show the protocol and representative traces for each variant. Altogether, these data demonstrate loss- and gain-of-function effects on channel activity for p.V469L and p.V471L, respectively.
POPC membranes. Each system was simulated for more than 1 µs in total. Figures 4A–4C displays simulation snapshots of the three ion channel systems and Videos S1–S6 show representative MD trajectories. We observed that the inner pore helices in p.V469L moved closer together at their hinge motif sites such that the pore became more constricted and fewer water molecules were able to enter the inner channel cavity through the cytosolic gate. This effect was most likely driven by increased attractive interactions between leucine 469 residues on adjacent and opposite S6 helices that led to a “de-wetting” of the channel pore. Calculation of the pore radius along the channel axis (z axis) (Figure 4D) confirmed that the K⁺ ion permeation pathway in the p.V469L channel is more constricted compared with WT and p.V471L Kv3.2 channels.

Furthermore, we noticed small but distinct differences of the backbone structure at residue 469 and preceding residues (Figure S4; Table S1). By contrast, the pore radius of the p.V471L channel was slightly wider than that of WT Kv3.2, indicating that p.V471L adopted a stable open conformation in MD. One possible explanation for this observation is the difference in the types of interactions made by residues at positions 469 and 471. While L469 side chains are oriented toward each other and toward the pore, L471 residues are oriented outward and interact with residues on S5 in the same subunit and with residues on S6 in a neighboring subunit. The largest number of atom contacts of L471 are made with Y480 on an adjacent S6 helix (Figure S5). In this variant, the number of heteroatom contacts (within 4 Å radius) for the L471-Y480 interaction more than doubled relative to the V471-Y480 interaction in WT Kv3.2 (average of ~3.2 contacts in WT Kv3.2 to ~7.0 contacts in the p.V471L channel). This finding offers a plausible explanation for how this amino acid change at position 471 leads to stabilization of the open channel conformation.

To assess the energetic cost more directly for K⁺ ion permeation in WT Kv3.2 and both channel variants, we used umbrella MD simulations and calculated the PMF for moving a K⁺ ion from the cytosolic site of the channel through the S6 helix gate into the water-filled cavity below the selectivity filter (Figure 5A). Compared with WT, the energetic barrier for ion transfer of the p.V469L variant increased by ~0.8 kcal/mol (Figure 5B). The p.V471L variant, however, required an energy for ion transfer similar to WT. The highest peak in the PMF and the p.V469L-specific energy increase occurred at position P470. This indicates that p.V469L, but not p.V471L, constricts the channel pore at the PVP hinge region, which is in line with our pore radius measurements.

In summary, MD simulations provided detailed insight into the molecular mechanism underlying the altered function of both variants. Our MD results agree well with the experimentally observed loss-of-function and gain-of-function phenotypes for p.V469L and p.V471L, respectively.

Discussion

Deriving actionable information for diagnosis and treatment from clinical sequencing data is a fundamental challenge in genetics and medicine. Current methods for analyzing sequencing data often fail due to the inability to predict the effects of the detected VUS on protein function. Here, we illustrate the power of a personalized structural biology pipeline that places candidate VUS into 3D structural models tailored to the individual. The integration of cycles of computational and experimental analysis enabled us to provide mechanistic molecular insights into the different mechanisms by which two proximal candidate KCNC2 VUSs lead to DEE-like phenotypes. DEE has been previously linked to dysfunction of other ion channels. Moreover, Kv3 channel family members have been previously associated with neurological disorders such as ataxias, epilepsies, schizophrenia, and Alzheimer disease.

The p.V469L variant occupies the central hydrophobic residue of the PVP motif and the flexibility of this hinge region is critical for channel opening and closing kinetics. Previous studies in other channels supported this hypothesis, as altering the central hydrophobic residues in Kv1.1 channels from valine to leucine, a constitutional isomer of leucine, affected channel kinetics, stability, and conformational dynamics. The p.V469L variant resulted in
A 50% decrease in peak current and a very slow deactivation with a slight negative shift (~10 mV). Interestingly, the p.V469L variant caused the Kv3.2 channel to be expressed at <50% of WT. Molecular dynamics simulations showed that the p.V469L variant had a smaller pore radius and a higher energetic barrier to ion transfer. The constriction was likely the result of hydrophobic interactions between bulkier L469 residues causing part of the channel pore to become devoid of water molecules.78,79

The V471 variant is immediately adjacent to the PVP hinge motif and resulted in a >50% increase in the peak current, with moderately slow deactivation, but a drastic negative shift (~28 mV). There was also an increase in protein expression to >150% of WT and the pore remained fully open in MD and the pore radius for the p.V471L variant of Kv3.2 channel was slightly wider. An increased number of inter-subunit contacts made by p.V471L suggests a possible mechanism how this mutant could selectively stabilize the open channel state. The p.V469L and p.V471L variants had heterogeneous loss-of-function and gain-of-function effects, respectively.

The lower current for p.V469L versus higher for p.V471L compared with WT could be explained by the differences in protein expression levels. However, alterations in the protein level would not cause changes in the kinetics of deactivation. The two variants could affect the energy required for the protein to undergo conformational changes between the open and closed states. The adjacency of the variants to the PVP motif would lead to changes to the ability of the helix to kink at the hinge.

Figure 4. The channel pore of Kv3.2 p.V469L becomes constricted in MD simulations, whereas the pore of p.V471L adopts a stable open conformation

(A–C) Snapshots from MD simulations of Kv3.2 WT (A), p.V469L (B), and p.V471L (C). The entire MD trajectories are shown in Videos S1–S6. For each protein, the channel-membrane system was simulated in four replicas with a total simulation time of more than 1 μs. The protein is represented as ribbon with each chain shown in a different color. One domain in the front is not shown to better see the channel cavity. The amino acids at positions 469 and 471 are depicted as spheres and colored cyan and yellow, respectively. Water molecules are shown as sticks (red-white).

(D) Surface representation of the pore radius of Kv3.2 WT (left) and 1D pore radius profiles (right) along the channel axis (z axis) for WT, p.V469L, and p.V471L. The solid line and shaded area represent the average radius and standard deviation from four independent MD replicas.
domain and facilitate channel gating. The p.V469L variant, which results in the central hydrophobic valine of the PVP motif to be substituted by a bulkier leucine extending into the pore, results in a lower tendency for the helix to kink and, therefore, leads to slower channel gating and slower deactivation. In contrast, the stabilization of the p.V471L channel in the “open” conformation, which would also affect channel gating, is consistent with its moderately slow deactivation. Thus, our results indicate that the variants influence both expression and channel function. However, our results do not identify the cause of the differences in the expression levels of the two variants. It is likely that these result from differences in protein folding or stability. However, further studies, such as analysis of the amount of protein on the membrane and protein trafficking in cells, are needed to identify the causes. For experimental simplicity, we carried out our in vitro and in silico analyses with all four chains carrying the variant of interest. In the future, it would be valuable to evaluate the spectrum of effects for channels carrying different combinations of variant and WT chains; although we anticipate similar effects. Furthermore, we note that our results are based on a computational model of Kv3.2; it will be valuable to revisit the modeling as additional models of Kv3.2 become available.

We have not simulated the entire dynamics involved in channel activation and deactivation. This process is too long to be studied by conventional MD methods. Enhanced MD protocols, which aim at representing the free energy landscape of the molecular system by a set of low-dimensional collective variables, have been used to simulate conformational changes for some ion channel systems.\cite{60,72,73} These methods could be helpful for explaining the observed changes in activation potential and deactivation time. However, no general protocol for deriving a set of collective variables that capture the whole activation and deactivation cycle of Kv channels, such as Kv3.2, is available yet.

The ability of the channel blocker 4-AP to inhibit the p.V469L Kv3.2 channel aligned with the loss-of-function phenotype because 4-AP approaches the channel lumen from the cytoplasm\cite{69,72,73}, therefore the steric hindrance of the pore cavity by p.V469L should not affect its mechanism of action. Furthermore, the decreased ability of 4-AP to block the p.V471L channel supports the gain-of-function hypothesis. Channel closing is destabilized in
p.V471L, so 4-AP may not bind as efficiently to the open channel. These results also illustrate how the personalized structural biology approach can help evaluate the effects of possible pharmacological interventions. For example, 4-AP is not likely to help individuals with the p.V449L variant, it is possible that it could counteract some effects of the p.V471L variant.

Taken together, the clinical features of the UDN and previously reported individuals and the combined experimental and molecular modeling of their de novo KCNC2 variants demonstrate their functional role as a cause of DEE. The phenotypes associated with the two variants in KCNC2 discussed in this work are the result of different molecular mechanisms, even though the residues are only two amino acids away. Analyses of these variants in their structural context was key to revealing their mechanistic and functional heterogeneity. Moreover, our results highlight the need to trace the complex mapping from genotype to disease phenotype via molecular functions. In addition to the contribution to diagnosis, our results also suggest that drugs that modulate the activity of Kv3.2 have different molecular consequences based on the presence of individual missense variants, further elaborating the necessity for a structural biology motivated personalized approach.

Several additional Kv3.2 variants were recently reported as candidates for epilepsy phenotypes.48 For example, four additional variants with functional evidence are: p.C125W and p.E135G in the cytosolic domain of the protein, p.F219S in the S1 helix at the base of the membrane, and p.T437A in the S5-S6 linker in the membrane (Figure S6A). T437A lies in the highly conserved and functionally important S5-S6 linker, which acts as the selectivity filter allowing only K⁺ ions through the channel. The variant alanine has one fewer methyl group than the reference threonine and lacks a polar hydroxyl group. We hypothesize that this variant might lead to a lowered specificity for potassium ions for the channel, and other ions may be allowed in as well, leading to disease phenotypes (Figure S6B). These highlight the diversity of molecular mechanisms by which variants in Kv3.2 may influence disease phenotypes. We are optimistic that more detailed structural modeling of these variants will suggest clear functional hypotheses.

This case study demonstrates the strength of personalized structural biology as a diagnostic method to predict precise molecular hypotheses by taking the context of the variant of interest in the 3D structure of the protein into account. The preliminary structural modeling steps can be performed within approximately 1 day on standard high-performance computer clusters, enabling the potential integration of the resulting insights into clinical decision making. Going forward, this approach has broad applicability across VUS observed in studies from rare disease to cancer.

**Consortium**

Undiagnosed Diseases Network, Maria T. Acosta, David R. Adams, Pankaj Agrawal, Mercedes E. Alejandro, Patrick Allard, Justin Alvey, Ashley Andrews, Euan A. Ashley, Mahshid S. Azamian, Carlos A. Bacino, Guney Bademci, Eva Baker, Ashok Balasubramanyam, Dustin Baldrige, Jim Bale, Deborah Barbouth, Gabriel F. Batzli, Pinar Bayrakt-Toydemir, Alan H. Beggs, Gill Bejermano, Hugo J. Bellen, Jonathan A. Bernstein, Gerard T. Berry, Anna Bican, David P. Bick, Camille L. Birch, Stephanie Bivona, John Bohnsack, Carsten Bonnenmann, Devon Bonner, Braden E. Boone, Bret L. Bostwick, Lorenzo Botto, Lauren C. Briere, Elly Brokamp, Donna M. Brown, Matthew Brussell, Elizabeth A. Burke, Lindsay C. Burrage, Manish J. Butte, John Carey, Olveen Carrasquillo, Ta Chen Peter Chang, Hsiao-Tuan Chao, Gary D. Clark, Terra R. Coakley, Laurel A. Cobban, F. Sessions Cole, Heather A. Colley, Cynthia M. Cooper, Heidi Cope, William J. Craig, Precilla D’Souza, Surendra Dasari, Mariska Davids, Jyoti G. Dayal, Esteban C. Dell’Angelica, Shweta U. Dhar, Naghmeh Dorrani, Daniel C. Dorset, Emilie D. Douine, David D. Draper, Laura Duncan, David J. Eckstein, Lisa T. Emrick, Christine M. Eng, Cecilia Esteves, Ty Estwick, Liliana Fernandez, Carlos Ferreira, Elizabeth L. Fieg, Paul G. Fisher, Brent L. Fogel, Irmanto Forghani, Laure Fresard, William A. Gahl, Rena A. Godfrey, Alicia M. Goldman, David B. Goldstein, Jean-Philippe F. Gourdine, Alana Grajewski, Catherine A. Groden, Andrea L. Groppman, Melissa Haendel, Neil A. Hanchard, Nichole Hayes, Frances High, Ingrid A. Holm, Jason Horn, Yong Huang, Alden Huang, Rosario Isasi, Fariha Jamal, Yong-Hui Jiang, Jean M. Johnston, Angela L. Jones, Lefkothea Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan Korrick, Mary Karaviti, Emily G. Kelley, Dana Kiley, David M Koeller, Isaac S. Kohane, Jennefer N. Kohler, Susan.
Data and code availability

The Kv3.2 3D structural model and MD simulation code and trajectories generated during this study are available in the supplemental files, supplemental videos, and the Capra lab Personalized Structural Biology GitHub repository (https://github.com/CapraLab/PSB). The values for the backbone dihedral phi (φ) and psi (ψ) angles in the protein structure at residue 469 and other proximal residues are shown in Figure S4 and are reported in Table S1.

Supplemental information

Supplemental information can be found online at https://doi.org/10.1016/j.xhgg.2022.100131.

Acknowledgments

First, we thank all affected UDN individuals and their families. We thank members of the Capra, Meiler, and UDN Labs for helpful comments. This work was conducted in part with the resources of the Advanced Computing Center for Research and Education at Vanderbilt University, Nashville, TN. This work was supported by awards from The National Institutes of Health (NIH) Common Fund, through the Office of Strategic Coordination and the Office of the NIH Director, to the clinical sites (U01HG007674 to Vander- 

The authors declare no competing interests.

References

1. Ng, S.B., Turner, E.H., Robertson, P.D., Flygare, S.D., Bigham, A.W., Lee, C., Shaffer, T., Wong, M., Bhattacharjee, A., Eichler, E.E., et al. (2009). Targeted capture and massively parallel sequencing of 12 human exomes. Nature 461, 272–276.
2. Ionita-Laza, I., Makarov, V., Yoon, S., Raby, B., Buxbaum, J., Nicolae, D.L., and Lin, X. (2011). ARTICLE finding disease variants in mendelian disorders by using sequence data: methods and applications. Am. J. Hum. Genet. 89, 701–712.
3. Ng, S.B., Buckingham, K.J., Lee, C., Bigham, A.W., Tabor, H.K., Dent, K.M., Huff, C.D., Shannon, P.T., Jabs, E.W., Nickerson, D.A., et al. (2010). Exome sequencing identifies the cause of a mendelian disorder. Nat. Genet. 42, 30–35.
4. Boycott, K.M., Rath, A., Chong, J.X., Hartley, T., Alkuraya, F.S., Baynham, G., Brooks, A.J., Brudno, M., Carracedo, A., Den Dunnen, J.T., et al. (2017). COMMENTARY International Cooperation to Enable the Diagnosis of All Rare Genetic Diseases.
5. Chong, J.X., Buckingham, K.J., Jhangiani, S.N., Boehm, C., Sobreira, N., Smith, J.D., Harrell, T.M., Mcmillin, M.J., Wiszniewski, W., Gambin, T., et al. (2015). The Genetic Basis of Mendelian Phenotypes: Discoveries, Challenges, and Opportunities.
6. Boycott, K.M., Hartley, T., Biesecker, L.G., Innes, A.M., Riess, O., Belmont, J., Dunwoodie, S.L., Lassmann, T., et al. (2019). A diagnosis for all rare genetic diseases: the horizon and the next frontiers. Cell 177, 32–37.
7. Gahl, W.A., Mulvihill, J.J., Toro, C., Markello, T.C., Wise, A.L., Ramoni, R.B., Adams, D.R., Tiffet, C.J.; and UD (2016). The NIH undiagnosed diseases program and Network: applications to modern medicine. Mol. Genet. Metab. 117, 393–400.
8. Gahl, W.A., Wise, A.L., and Ashley, E.A. (2015). The undiagnosed diseases Network of the National Institutes of Health. JAMA 314, 1797–1798.
9. Ramoni, R.B., Mulvihill, J.J., Adams, D.R., Allard, P., Ashley, E.A., Bernstein, J.A., Gahl, W.A., Hamid, R., Loscalzo, J., McCray, A.T., et al. (2017). The undiagnosed diseases Network: accelerating discovery about Health and disease. Am. J. Hum. Genet. 100, 185–192.
10. Niroula, A., and Vihinen, M. (2016). Variation Interpretation Predictors: Principles, Types, Performance, and Choice (John Wiley and Sons Inc.).
11. Tang, H., and Thomas, P.D. (2016). Tools for predicting the functional impact of nonsynonymous genetic variation. Genetics 203, 635–647.
12. Peterson, T.A., Doughty, E., and Kann, M.G. (2013). Towards precision medicine: advances in computational approaches for the analysis of human variants. J. Mol. Biol. 425, 4047–4063.
13. Thusberg, J., Olatubosun, A., and Vihinen, M. (2011). Performance of mutation pathogenicity prediction methods on missense variants. Hum. Mutat. 32, 358–368.
14. Niroula, A., and Vihinen, M. (2017). Predicting severity of disease-causing variants. Hum. Mutat. 38, 357–364.
15. Riera, C., Padilla, N., and de la Cruz, X. (2016). The complementarity between protein-specific and general pathogenicity predictors for amino acid substitutions. Hum. Mutat. 37, 1013–1024.
16. Grimm, D.G., Azencott, C.A., Aicheler, F., Gieraths, U., Macarthur, D.G., Samocha, K.E., Cooper, D.N., Stenson, P.D., Daly, M.J., Smoller, J.W., et al. (2015). The evaluation of tools used to predict the impact of missense variants is hindered by two types of circularity. Hum. Mutat. 36, 513–523.
17. Vihinen, M. (2021). Functional effects of protein variants. Biochimie 180, 104–120.
comparative modeling with RosettaCM. Structure 21, 1735–1742.

52. Barth, P., Wallner, B., and Baker, D. (2009). Prediction of membrane protein structures with complex topologies using limited constraints. Proc. Natl. Acad. Sci. USA 106, 1409–1414.

53. DiMaio, F., Leaver-Fay, A., Bradley, P., Baker, D., and André, I. (2011). Modeling symmetric macromolecular structures in Rosetta3. PLoS One 6, 20450.

54. Lomize, M.A., Pogozheva, I.D., Joo, H., Mosberg, H.I., and Lomize, A.L. (2012). OPM database and PPM web server: resources for positioning of proteins in membranes. Nucleic Acids Res. 40, D370–D376.

55. Wu, E.L., Cheng, X., Jo, S., Rui, H., Song, K.C., Davila-Contreas, E.M., Qi, Y., Lee, J., Monje-Galvan, V., Venable, R.M., et al. (2014). CHARMM-GUI membrane builder toward realistic biological membrane simulations. J. Comput. Chem. 35, 1997–2004.

56. Case, D.A., Betz, R.M., Cerutti, D.S., Cheatham, T.E., III, Darden, T.A., Duke, R.E., Giese, T.J., Gohlke, H., Goetz, A.W., Homey, N., et al. (2016). Principal Contributors to the Current Codes : Amber 2016 Reference Manual (AMBER 2016, Univ. California).

57. Maier, J.A., Martínez, C., Kasavajhala, K., Wickstrom, L., Hauser, K.E., and Simmerling, C. (2015). f3SGB: improving the accuracy of the protein side chain and backbone parameters from f99SB. J. Chem. Theory Comput. 11, 3696–3713.

58. Ryckaert, J.-P., Ciccotti, G., and Berendsen, H.J. (1977). Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 23, 327–341.

59. Darden, T., York, D., and Pedersen, L. (1993). Particle mesh Ewald: an N-log(N) method for Ewald sums in large systems. J. Chem. Phys. 98, 10089–10092.

60. Roe, D.R., and Cheatham, T.E. (2013). PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J. Chem. Theory Comput. 9, 3084–3095.

61. Smart, O.S., Neduvelil, J.G., Wang, X., Wallace, B.A., and Sanbonmatsu, K.Y. (2013). PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J. Chem. Theory Comput. 9, 100131, October 13, 2022.

62. Fowler, P.W., and Sansom, M.S.P. (2013). The pore of voltage-gated potassium ion channels is strained when closed. Nat. Commun. 4, 1872–1878.

63. Kumar, S., Rosenberg, J.M., Bouzida, D., Swendsen, R.H., and Kollman, P.A. (1992). The weighted histogram analysis method for free-energy calculations on biomolecules. I. The method. J. Comput. Chem. 13, 1011–1021.

64. Grossfield, A. WHAM: The Weighted Histogram Analysis Method.

65. Leaver-Fay, A., Tyka, M., Lewis, S.M., Lange, O.F., Thompson, J., Jacak, R., Kaufman, K., Renfrew, P.D., Smith, C.A., Sheffler, W., et al. (2011). Rosetta3: an object-oriented software suite for the simulation and design of macromolecules. In Methods in Enzymology, pp. 545–574.

66. Imbrii, P., Grottesi, A., D’Adamo, M.C., Mannucci, R., Tucker, S.J., and Pessia, M. (2009). Contribution of the central hydrophobic residue in the PXP motif of voltage-dependent K+ channels to S6 flexibility and gating properties. Channels 3, 39–45.

67. Rudy, B., Chow, A., Lau, D., Amarillo, V., Ozaita, A., Saganich, M., Moreno, H., Nadal, M.S., Hernandez-Pineda, R., Hernandez-Cruz, A., et al. (1999). Contributions of Kv3 channels to neuronal excitability. In Annals of the New York Academy of Sciences (New York Academy of Sciences), pp. 304–343.

68. Erisir, A., Lau, D., Rudy, B., and Leonard, C.S. (1999). Function of specific K+ channels in sustained high-frequency firing of fast-spiking neocortical interneurons. J. Neurophysiol. 82, 2476–2489.

69. Kirsch, G.E., and Drew, J.A. (1993). Gating-dependent mechanism of 4-aminopyridine block in two related potassium channels. J. Gen. Physiol. 102, 797–816.

70. Alviña, K., and Khodakhah, K. (2010). The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia. J. Neurosci. 30, 7258–7268.

71. Chang, K.W., Yuan, T.C., Fang, K.P., Yang, F.S., Liu, C.J., Chang, C.S., and Lin, S.C. (2003). The increase of voltage-gated potassium channel Kv3.4 mRNA expression in oral squamous cell carcinoma. J. Oral Pathol. Med. 32, 606–611.

72. Armstrong, C.M., and Loboda, A. (2001). A model for 4-aminopyridine action on K channels: similarities to tetraethylammonium ion action. Biophys. J. 81, 895–904.

73. Choquet, D., and Korn, H. (1992). Mechanism of 4-Aminopyridine Action on Voltage-Gated Potassium Channels in Lymphocytes.

74. Van Hoeymissen, E., Held, K., Nogueira Freitas, A.C., Janssen, A., Voets, T., and Vriens, J. (2020). Gain of channel function and modified gating properties in TRPM3 mutants causing intellectual disability and epilepsy. Elife 9, e57190-12.

75. Crawford, K., Xian, J., Helbig, K.L., Galer, P.D., Parthasarathy, S., Lewis-Smith, D., Kaufman, M.C., Fitch, E., Ganesan, S., O’Brien, M., et al. (2021). Computational analysis of 10, 860 phenotypic annotations in individuals with SCN2A-related disorders. Genet. Med. 23, 1263–1272.

76. Kaczmarek, L.K., and Zhang, Y. (2017). Kv3 channels: enablers of rapid firing, neurotransmitter release, and neuronal endurance. Physiol. Rev. 97, 1431–1468.

77. Labro, A., Aryal, P., Sansom, M.S.P., and Tucker, S.J. (2015). Hydrophobic gating in ion channels. J. Mol. Biol. 427, 121–130.

78. Levy, B., Murail, S., Poitevin, F., Cromer, B.A., Baaden, M., Delarue, M., and Allen, T.W. (2017). String method solution of the gating pathways for a pentameric ligand-gated ion channel. Proc. Natl. Acad. Sci. USA 114, E4158–E4167.